The association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk

References

• Sachdev PS. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am 2005;28:255–74.
   PubMed Web of Science ®Google Scholar
• Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;11:34–42.
   PubMed Web of Science ®Google Scholar
• Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med 2009;39:1065–76.
   PubMed Web of Science ®Google Scholar
• Ryu S, Yoo JH, Kim JH, et al. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study. J Clin Psychopharmacol 2015;35:13–21.
   PubMed Web of Science ®Google Scholar
• Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8:52s–6s.
   PubMed Web of Science ®Google Scholar
• Koning JP, Vehof J, Burger H, et al. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl) 2012;219:727–36.
   PubMed Web of Science ®Google Scholar
• Miura I, Zhang JP, Nitta M, et al. BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis. Schizophr Res 2014;152:365–72.
   PubMed Web of Science ®Google Scholar
• Zai CC, Tiwari AK, Mazzoco M, et al. Association study of the vesicular monoamine transporter gene Slc18a2 with tardive dyskinesia. J Psychiatr Res 2013;47:1760–5.
   PubMed Web of Science ®Google Scholar
• Syu A, Ishiguro H, Inada T, et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacology 2010;35:1155–64.
   PubMed Web of Science ®Google Scholar
• Greenbaum L, Alkelai A, Zozulinsky P, et al. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 2012;12:513–20.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Syu A, Ishiguro H, et al. DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia. Pharmacogenomics J 2013;13:27–34.
   PubMed Web of Science ®Google Scholar
• Segman RH, Heresco-Levy U, Yakir A, et al. Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiatry 2002;51:261–3.
   PubMed Web of Science ®Google Scholar
• Son W-Y, Lee H-J, Yoon H-K, et al. Gaba transporter Slc6a11 gene polymorphism associated with tardive dyskinesia. Nordic J Psychiatry 2014;68:123–8.
   PubMed Web of Science ®Google Scholar
• Matsumoto C, Shinkai T, Hori H, et al. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry Res 2004;127:1–7.
   PubMed Web of Science ®Google Scholar
• Srivastava V, Varma PG, Prasad S, et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006;16:111–7.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Zeitoun KM, Kilic G. Expression of dioxin-related transactivating factors and target genes in human eutopic endometrial and endometriotic tissues. Am J Obstet Gynecol 2000;182:767–75.
   PubMed Web of Science ®Google Scholar
• Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34:4202–10.
   PubMed Web of Science ®Google Scholar
• Fan CH, Li LH, Fu Y, et al. An association study on catechol-O-methyltransferase gene polymorphism and tardive dyskinesia. Chin J Behavioral Med Sci (Chinese) 2007;16:16–7.
   Google Scholar
• Herken H, Erdal ME, Boke O, et al. Tardive dyskinesia is not associated with the polymorphisms of 5-Ht2a receptor gene, serotonin transporter gene and catechol-O-methyltransferase gene. Eur Psychiatry 2003;18:77–81.
   PubMed Web of Science ®Google Scholar
• Han D, Lee J, Lee Y, et al. The association between tardive dyskinesia induced by haloperidol and polymorphisms in the serotonin transporter gene and catecholamine-O-methyltransferase gene in Korean schizophrenic patients. Clin Psychopharmacol Neurosci 2005;3:16–21.
   Google Scholar
• Kang S-G, Choi J-E, Park Y-M, et al. Val158Met polymorphism in the catechol-O-methyltransferase (COMT) gene is not associated with tardive dyskinesia in schizophrenia. Neuropsychobiology 2008;57:22–5.
   PubMed Web of Science ®Google Scholar
• Lai IC, Wang YC, Lin CC, et al. Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. J Neural Transm 2005;112:1107–13.
   PubMed Web of Science ®Google Scholar
• Li H, Tan Y, Wang Z, et al. Association study on tardive dyskinesia and polymorphisms in COMT and MAOA in Chinese population. Psychiatr Genet 2013;23:176.
   PubMed Web of Science ®Google Scholar
• Hu WH, Jiang KD, Wang DX, et al. Association study between catechol-O-methyltransferase gene polymorphism and tardive dyskinesia. Shanghai Arch Psychiatry (Chinese) 2007;19:264–6.
   Google Scholar
• Liu SS, Zhang YY, Yue Y, et al. Analysis on association between COMT gene polymorphism and tardive dyskinesia induced by antipsychotic drugs. J Jilin Univ (Med Ed) (Chinese) 2011;37:487–90.
   Google Scholar
• Zai CC, Tiwari AK, Müller DJ, et al. The catechol-O-methyl-transferase gene in tardive dyskinesia. World J Biol Psychiatry 2010;11:803–12.
   PubMed Web of Science ®Google Scholar
• Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry 2013;46:207–13.
   PubMed Web of Science ®Google Scholar
• Staddon S, Arranz MJ, Mancama D, et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl) 2002;162:18–23.
   PubMed Web of Science ®Google Scholar
• Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 2011;25:933–69.
   PubMed Web of Science ®Google Scholar
• Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980;37:1368–73.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Cole JO, Davis JM, et al. Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. By the task force on late neurological effects of antipsychotic drugs. Am J Psychiatry 1980;137:1163–72.
   PubMed Web of Science ®Google Scholar
• Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18:701–15.
   PubMed Web of Science ®Google Scholar
• Li CT, Chou KH, Su TP, et al. Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study. PLoS One 2013;8:e71034.
   PubMed Web of Science ®Google Scholar
• Bakker PR, Al Hadithy AF, Amin N, et al. Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 Tag SNPS in 7 candidate genes: a prospective study. PLoS One 2012;7:e50970.
   PubMed Web of Science ®Google Scholar
• Boskovic M, Vovk T, Saje M, et al. Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia. Neurochem Res 2013;38:433–42.
   PubMed Web of Science ®Google Scholar
• Nackley A, Shabalina S, Tchivileva I, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering MRNA secondary structure. Science 2006;314:1930–3.
   PubMed Web of Science ®Google Scholar
• Li H, Tan Y, Wang Z, et al. Association study on tardive dyskinesia and polymorphisms in COMT and MAOA in Chinese population. Psychiatr Genet 2013;23:176.
   PubMed Web of Science ®Google Scholar
• Bakker P, Van Harten P, Van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MNSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008;13:544–56.
   PubMed Web of Science ®Google Scholar